Biohaven Ltd. today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300 is the first MoDE extracellular protein degrader, a novel small ...
Sobi® today announced new data across its haemophilia portfolio will be presented at the 2026 Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Paris, from 11 ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and severe immune-mediated disease that affects sensory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results